Loading
ZEeST Bio is developing radioactive medicines that use the liver's own uptake biology to carry radiation into liver tumours, with the same agent used for scanning. Its lead programme is for hepatocellular carcinoma, the commonest primary liver cancer, and is in laboratory testing.
ZEeST Bio develops a theranostic radiopharmaceutical platform for liver cancers built on a clinically validated liver-targeting mechanism, designed so one agent serves both imaging and therapy. Its lead programme ZST-101 is in preclinical development for hepatocellular carcinoma, with extension planned to hepatoblastoma and fibrolamellar carcinoma. The founder and chief executive, Khashayar Vakili, is a hepatobiliary and liver transplant surgeon. In fiscal year 2026 NCI awarded it USD 398,040 under SBIR award 1R43CA310036-01A1 to develop a pre-targeting strategy for liver cancer radionuclide therapy.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R43) 1R43CA310036-01A1: Development of a Pre-Targeting Strategy for Liver Cancer Radionuclide Therapy | 2026 | $398K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
ZST-101 is an experimental radioactive medicine from ZEeST Bio for hepatocellular carcinoma, the commonest primary liver cancer. It is in laboratory testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/